We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · November 16, 2021

ACAAI 2021: Ligelizumab’s Ability to Produce Freedom From Disease Activity in Chronic Spontaneous Urticaria Unaffected by Baseline H1 Antihistamine Dose

Ligelizumab produced complete remission in one-third to one-half of patients, regardless of baseline H1 antihistamine dose

PracticeUpdate Editorial Team


Further Reading